MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
17.76%
Quick Ratio
17.76%
Debt to Asset Ratio
526.71%
Unit: Dollar
Assets Breakdown
    • Cash
    • Operating lease right-of-use ass...
    • Equipment and furnishings, less ...
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Convertible notes payable-Nonrel...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash
1,156,915
223,883
251,291
72,479
Prepaid expenses and other current assets
211,969
236,502
316,583
205,509
Total current assets
1,368,884
460,385
567,874
277,988
Equipment and furnishings, less accumulated depreciation of 120,945 and 120,013, respectively
2,068
2,534
3,000
3,465
Operating lease right-of-use asset
102,549
114,661
126,628
138,451
Total assets
1,473,501
577,580
697,502
419,904
Accounts payable
931,972
815,315
716,220
1,177,776
Accrued interest-Nonrelated Party
49,469
38,300
23,540
44,133
Accrued interest-Related Party
114,154
119,545
120,384
97,450
Other accrued expenses
3,159,127
3,568,311
3,161,379
2,824,285
Notes payable
92,443
161,265
217,772
105,860
Convertible notes payable-Nonrelated Party
2,075,000
980,000
870,000
1,050,000
Convertible notes payable-Related Party
1,235,000
1,510,000
1,740,000
1,125,000
Operating lease liability, current portion
49,980
49,025
48,083
47,152
Total current liabilities
7,707,145
7,241,761
6,897,378
6,471,656
Notes payable, non-current portion
-
-
23,621
23,621
Operating lease liability, non-current portion
53,920
66,649
79,221
91,637
Total liabilities
7,761,065
7,308,410
7,000,220
6,586,914
Preferred stock value-Series DConvertible Preferred Stock
957
957
957
957
Preferred stock value-Series DOne Convertible Preferred Stock
14,748
14,355
14,183
13,975
Common stock par value 0.001 per share 1,000,000,000 shares authorized 420,279,879 shares issued and outstanding at june 30, 2026 and december 31, 2025
420,280
420,280
420,280
420,280
Additional paid-in capital
258,475,479
257,043,993
256,179,846
255,163,053
Accumulated other comprehensive loss
-59,803
-59,906
-60,191
-60,327
Accumulated deficit
-265,126,832
-264,144,266
-262,853,812
-261,688,770
Total provectus biopharmaceuticals, inc., stockholders deficit
-6,275,171
-6,724,587
-6,298,737
-6,150,832
Non-controlling interest in subsidiary
-12,393
-6,243
-3,981
-16,178
Total stockholders deficit
-6,287,564
-6,730,830
-6,302,718
-6,167,010
Total liabilities and stockholders deficit
1,473,501
577,580
697,502
419,904
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash$1,156,915 (199.77%↑ Y/Y)Prepaid expenses andother current assets$211,969 (39.59%↑ Y/Y)Total current assets$1,368,884 (140.87%↑ Y/Y)Operating leaseright-of-use asset$102,549 (-31.69%↓ Y/Y)Equipment andfurnishings, less...$2,068 (-47.39%↓ Y/Y)Accumulated deficit-$265,126,832 (-1.82%↓ Y/Y)Accumulated othercomprehensive loss-$59,803 (0.92%↑ Y/Y)Total assets$1,473,501 (103.98%↑ Y/Y)Total provectusbiopharmaceuticals, inc.,...-$6,275,171 (-6.89%↓ Y/Y)Non-controlling interest insubsidiary-$12,393 (-223.58%↓ Y/Y)Additional paid-in capital$258,475,479 (1.71%↑ Y/Y)Common stock par value0.001 per share...$420,280 (0.00%↑ Y/Y)Preferred stockvalue-Series DOne...$14,748 (7.46%↑ Y/Y)Preferred stockvalue-Series DConvertible...$957 (0.00%↑ Y/Y)Total liabilities andstockholders deficit$1,473,501 (103.98%↑ Y/Y)Total stockholdersdeficit-$6,287,564 (-7.03%↓ Y/Y)Total liabilities$7,761,065 (17.64%↑ Y/Y)Total currentliabilities$7,707,145 (18.69%↑ Y/Y)Operating leaseliability, non-current...$53,920 (-48.10%↓ Y/Y)Other accruedexpenses$3,159,127 (20.42%↑ Y/Y)Convertible notespayable-Nonrelated Party$2,075,000 (219.23%↑ Y/Y)Convertible notespayable-Related Party$1,235,000 (-25.60%↓ Y/Y)Accounts payable$931,972 (-28.91%↓ Y/Y)Accruedinterest-Related Party$114,154 (-6.33%↓ Y/Y)Notes payable$92,443 (70.13%↑ Y/Y)Operating leaseliability, current portion$49,980 (8.11%↑ Y/Y)Accruedinterest-Nonrelated Party$49,469 (87.78%↑ Y/Y)

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)